<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013121015740N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-05-04</date_registration>
      <primary_sponsor>Vice chancellor for research, Tehran Univercity of Medcal Sciences</primary_sponsor>
      <public_title>Effect of intravenous fluid sodium concentration on plasma sodium in pediatric patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effects of intravenous fluid with different concentrations of sodium on serum sodium levels in patients admitted to the intensive care unit of Bahrami Children's Hospital in 2012-13.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-12-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/14917</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Hyponatremia.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, in children over1 , the maintenance intravenous fluid with the common volume and calculated based on the Holliday-Segar formula containing 100 MEq of sodium per liter has been used and in children under 1, 50 MEq of sodium has been used. In addition to sodium, the intravenous fluid contains potassium at 20 MEq per one liter of fluid and glucose with a concentration of 10 g/L, respectively. The volume of the received fluid will be calculated based on the Holliday-segar formula; thus, for the first 10 kilograms, 100 cc weigh per kilogram of weight and for the second 10 kilogram, 50 cc per kilogram weight and for the rest of the weight, 20 cc per kilogram weight of the intravenous fluid are prescribed during 24 hours. Intervention 2: In the control group, in children over 1 years old the maintenance intravenous fluid with the common volume and calculated through the Holliday-Segar formula containing 50 MEq of sodium per liter has been used and in children under 1 years old, 30 MEq of sodium has been used. In addition to sodium, the intravenous fluid contains potassium at 20 MEq per one liter of fluid and glucose with a concentration of 10 g/L, respectively. The volume of the received fluid will be calculated based on the Holliday-segar formula; thus, for the first 10 kilograms, 100 cc weigh per kilogram of weight and for the second 10 kilogram, 50 cc per kilogram weight and for the rest of the weight, 20 cc per kilogram weight of the intravenous fluid are prescribed during 24 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Motahare Aghajani Delavar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghasem abad st, Shahid Khaei</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 4441 2447</telephone>
        <email>maghajani@razi.tums.ac.ir; aghajani_14@yahoo.com</email>
        <affiliation>Tehran Univercity of Medcal Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Dariush Fahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghasem abad st, Shahid Kiaei</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 7301 3000</telephone>
        <email>fahimida@sina.tums.ac.ir</email>
        <affiliation>Tehran Univercity of Medcal Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: children in the age range 30 days to 14 years for his doctor prescribe intravenous fluid and pain for at least 24 hours in hospital pediatric intensive care Bahrami,Tehran University of Medical are admitted users.&#13;
 Exclusion criteria: patients with acute or chronic renal parenchymal problems, such as diabetic ketoacidosis and cerebral edema in patients at risk of trauma to the head, heart disease; hypoglycemic patients; patients with abnormal secretion of antidiuretic hormone; diabetes insipidus; pituitary or hypothalamic disorders. patients underwent surgery to have lost a lot of blood during surgery, and cranial thoracic surgery patients; cirrhotic patients; patients with severe malnutrition; diabetes, and his doctor to his patient fluid therapy in a framework designed this study can not reject.&#13;
Withdrawal criteria; The research indicates that children with higher serum sodium lower than the normal range (135_145); the need to take CPR; being intubated; the death; early oral feeding; or any condition that a doctor's decision to withdraw his case if the study or decide to change intravenous fluids may be excluded.</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E87.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypo-osmolality and Hyponatremia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, in children over1 , the maintenance intravenous fluid with the common volume and calculated based on the Holliday-Segar formula containing 100 MEq of sodium per liter has been used and in children under 1, 50 MEq of sodium has been used. In addition to sodium, the intravenous fluid contains potassium at 20 MEq per one liter of fluid and glucose with a concentration of 10 g/L, respectively. The volume of the received fluid will be calculated based on the Holliday-segar formula; thus, for the first 10 kilograms, 100 cc weigh per kilogram of weight and for the second 10 kilogram, 50 cc per kilogram weight and for the rest of the weight, 20 cc per kilogram weight of the intravenous fluid are prescribed during 24 hours.</i_keyword>
      <i_keyword>In the control group, in children over 1 years old the maintenance intravenous fluid with the common volume and calculated through the Holliday-Segar formula containing 50 MEq of sodium per liter has been used and in children under 1 years old, 30 MEq of sodium has been used. In addition to sodium, the intravenous fluid contains potassium at 20 MEq per one liter of fluid and glucose with a concentration of 10 g/L, respectively. The volume of the received fluid will be calculated based on the Holliday-segar formula; thus, for the first 10 kilograms, 100 cc weigh per kilogram of weight and for the second 10 kilogram, 50 cc per kilogram weight and for the rest of the weight, 20 cc per kilogram weight of the intravenous fluid are prescribed during 24 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Plasma concentrations of sodium. Timepoint: 24 hours after initiation of intravenous fluid. Method of measurement: Sodium concentration in the blood sample.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Complications Haypvnatrmy. Timepoint: During and after reading. Method of measurement: Clinical interviews with hospital doctors.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Tehran Univercity of Medcal Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-05-21</approval_date>
        <contact_name>Medical Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Keshavarz st.Ghods st. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
